Suppr超能文献

接受扩大标准供体和非扩大标准供体死亡供肾再次移植受者的死亡情况

Mortality experience in recipients undergoing repeat transplantation with expanded criteria donor and non-ECD deceased-donor kidneys.

作者信息

Miles C D, Schaubel D E, Jia X, Ojo A O, Port F K, Rao P S

机构信息

Department of Medicine, University of Michigan, Ann Arbor, MI, USA.

出版信息

Am J Transplant. 2007 May;7(5):1140-7. doi: 10.1111/j.1600-6143.2007.01742.x. Epub 2007 Feb 27.

Abstract

Nearly one-quarter of the kidney transplant waiting list is composed of repeat transplantation candidates. Survival following retransplantation using expanded criteria donor (ECD) kidneys has not been adequately studied. Using data from the Scientific Registry of Transplant Recipients, we analyzed mortality after retransplantation with ECD and non-ECD deceased-donor kidneys. Adult patients who experienced graft failure and were relisted for transplantation between 1995 and 2004 were studied (n=9641). Follow-up began at the date of relisting and continued until death or the end of the observation period (December 31, 2004), with censoring at living-donor transplantation. Sequential stratification (an extension of Cox regression) was used to compare mortality between patients receiving an ECD retransplant and those remaining on the waiting list or receiving a non-ECD retransplant (conventional therapy). Of 2908 retransplantations, 292 used ECD kidneys. Survival after ECD retransplantation was approximately equal to that of conventional therapy, with an adjusted hazard ratio of 0.98 (p=0.88). In contrast, non-ECD retransplant recipients experienced a significant reduction in mortality (HR=0.44; p<0.0001). Based on these national data, recipients of ECD retransplantation do not have a survival advantage relative to conventional therapy, whereas non-ECD retransplantation is associated with a significant survival advantage.

摘要

肾移植等待名单上近四分之一是再次移植的候选者。使用扩展标准供体(ECD)肾脏进行再次移植后的存活率尚未得到充分研究。利用移植受者科学注册中心的数据,我们分析了使用ECD和非ECD死亡供体肾脏进行再次移植后的死亡率。对1995年至2004年间经历移植失败并重新列入移植名单的成年患者进行了研究(n = 9641)。随访从重新列入名单之日开始,持续至死亡或观察期结束(2004年12月31日),活体供体移植时进行截尾。采用序贯分层(Cox回归的扩展)来比较接受ECD再次移植的患者与仍在等待名单上或接受非ECD再次移植(传统治疗)的患者之间的死亡率。在2908例再次移植中,292例使用了ECD肾脏。ECD再次移植后的存活率与传统治疗大致相当,调整后的风险比为0.98(p = 0.88)。相比之下,非ECD再次移植受者的死亡率显著降低(HR = 0.44;p < 0.0001)。基于这些全国性数据,ECD再次移植受者相对于传统治疗没有生存优势,而非ECD再次移植则具有显著的生存优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验